home / stock / acrs / acrs news

ACRS News and Press, Aclaris Therapeutics Inc. From 11/13/23

Stock Information
Company Name: Aclaris Therapeutics Inc.
Stock Symbol: ACRS
Market: NASDAQ
Website: aclaristx.com
Menu
ACRS ACRS Quote ACRS Short ACRS News ACRS Articles ACRS Message Board
Get ACRS Alerts

News, Short Squeeze, Breakout and More Instantly...
ACRS - Aclaris plummets as mid-stage trial for arthritis therapy fails

2023-11-13 07:56:03 ET More on Aclaris Aclaris Therapeutics: The Many Lives Of This Biopharmaceutical Developer Aclaris Therapeutics rises 13% on insider buy Seeking Alpha’s Quant Rating on Aclaris Therapeutics Historical earnings data for Aclaris Ther...
ACRS - Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update

— Study Did Not Meet Primary or Secondary Efficacy Endpoints in Rheumatoid Arthritis — — Efficacy Results Do Not Support Further Development of Zunsemetinib — — Company to Host Conference Call and Webcast Today at 8:00 AM ET ...

ACRS - Expected earnings - Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc. (ACRS) is expected to report $-0.48 for Q3 2023

ACRS - Aclaris Therapeutics GAAP EPS of -$0.41 beats by $0.07, revenue of $9.28M

2023-11-06 07:20:03 ET More on Aclaris Therapeutics Aclaris Therapeutics: The Many Lives Of This Biopharmaceutical Developer Aclaris Therapeutics rises 13% on insider buy Seeking Alpha’s Quant Rating on Aclaris Therapeutics Historical earnings data for...
ACRS - QURE, GREE and AUR are among after hour movers

2023-10-04 17:50:03 ET Gainers: Prime Medicine ( NASDAQ: PRME ) +5% . uniQure ( QURE ) +5% . Aclaris Therapeutics ( ACRS ) +4% . ALX Oncology Holdings  ( ALXO ) +3% . Aurora Innovation ( AUR ) +3% . Losers: MaxCy...

ACRS - Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)

- Top-line Data Anticipated Around Year End WAYNE, Pa., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the completion of...

ACRS - MQ, BIOR and ACRS are among after hour movers

2023-09-28 17:12:16 ET Gainers: Editas Medicine ( NASDAQ: EDIT ) +8% . Marqeta ( MQ ) +3% . Cipher Mining ( CIFR ) +3% . Aclaris Therapeutics ( ACRS ) +2% . Biora Therapeutics ( BIOR ) +2% . Losers: Jaguar Global Grow...
ACRS - Aclaris Therapeutics: The Many Lives Of This Biopharmaceutical Developer

2023-09-28 07:18:10 ET Summary Aclaris Therapeutics is a developer of kinome-based medicines for immune-inflammatory and oncology indications. The company's platform, KINect, helps advance small molecules targeting kinases to replicate or improve the effects of expensive biologics...

ACRS - Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference

WAYNE, Pa., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fire...

ACRS - Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor

– Preliminary Data Support Progression to Phase 2a Proof of Concept Trials in T cell-mediated Autoimmune Diseases – WAYNE, Pa., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on dev...
Previous 10 Next 10